Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Table 2 Actigraphy endpoints (full analysis set)

Endpoint	Treatment	Baseline value, mean	Change from baseline
Endpoint	Treatment	Baseline value, mean	LS mean (95 % CI)^aor mean (SD)^b	LS mean difference (95 % CI)^aor mean (SD)^b
Duration of at least moderate activity per day, minutes	IND/GLY	125	-6.9 (-13.4, -0.4)	4.4 (-3.3, 12.1; p = 0.264)
Duration of at least moderate activity per day, minutes	Placebo	130	-11.3 (-17.9, -4.6)	4.4 (-3.3, 12.1; p = 0.264)
Average number of steps per day	IND/GLY	5602	31 (1662.4)	358 (2458.0; p = 0.029)
Average number of steps per day	Placebo	5849	-321 (1647.6)	358 (2458.0; p = 0.029)
Average physical activity	IND/GLY	1.49	0.01 (0, 0.03)	0.02 (0, 0.04); p = 0.019
Average physical activity	Placebo	1.50	-0.01 (-0.03, 0.01)	0.02 (0, 0.04); p = 0.019

ISSN: 1471-2466